Table 4.
Drugs involved in drug‐related death cases
| Drug | n | % | Drug–drug interaction |
|---|---|---|---|
| Acetylsalicylic acid | 20 | 17.2% | 4 (20%) |
| Prednisone | 15 | 12.9% | 13 (86.7%) |
| Acenocoumarol | 11 | 9.5% | 1 (9.1%) |
| Dexamethasone | 6 | 5.2% | 5 (83.3%) |
| Ciclosporin | 5 | 4.3% | 5 (100%) |
| Clopidogrel | 4 | 3.4% | 3 (75%) |
| 5‐Fluorouracil | 3 | 2.6% | 2 (100%) |
| Mycophenolic acid | 3 | 2.6% | 3 (100%) |
| Methotrexate | 3 | 2.6% | 2 (66.7%) |
| Enoxaparin | 2 | 1.7% | 0 (0%) |
| Pentoxifylline | 2 | 1.7% | 2 (100%) |
| Bevacizumab | 2 | 1.7% | 2 (100%) |
| Pemetrexed | 2 | 1.7% | 2 (100%) |
| Paclitaxel | 2 | 1.7% | 1 (50%) |
| Tacrolimus | 2 | 1.7% | 2 (100%) |
| Topotecan | 2 | 1.7% | 2 (100%) |
| Amiodarone, azacitidine, azathioprine, bendamustine, blinatumomab, carboplatin, carmustine, ceritinib, cetuximab, cyclophosphamide, cytarabine, dexketoprofen, docetaxel, doxorubicin, etoposide, everolimus, fentanyl, furosemide, gemcitabine, ivabradine, leflunomide, lorazepam, melphalan, mitomycin, nilotinib, nivolumab, oxaliplatin, paracetamol, rituximab, ruxolitinib, sertraline, venlafaxine | 1 each (32) | 0.9% each | 0 |
| Total | 116 | 100 | 48 drugs (41%) |